METHODOLOGY FOR EVALUATING MEANINGFUL CHANGE THRESHOLDS IN PATIENT-REPORTED OUTCOME (PRO) MEASURES FOR CORNEAL EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF)

被引：0
|
作者：
Eliason, L. [1 ]
Loubert, A. [2 ]
Gorsh, B. [1 ]
Meunier, J. [2 ]
Kleinman, D. [3 ]
Sapra, S. [1 ]
Regnault, A. [2 ]
机构：
[1] GlaxoSmithKline, Upper Providence, PA USA
[2] Modus Outcomes, Lyon, France
[3] Univ Rochester, Flaum Eye Inst, Rochester, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN309
引用
收藏
页码：S477 / S477
页数：1
相关论文
共 46 条
  • [21] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
  • [22] Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/ Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante-Barrigon, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Greil, Richard
    Melchardt, Thomas
    Antonioli, Elisabetta
    Schjesvold, Fredrik
    Lysen, Anna
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    Mouro, Jorge
    D'Estrube, Tim
    Fry, Mark
    Byrne, Julie
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S277 - S278
  • [23] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) cytogenetics
    Besemer, B.
    Cohen, A. D.
    Trudel, S.
    Lonial, S.
    Libby, E.
    Lee, H. C.
    Facon, T.
    Nooka, A. K.
    Callander, N.
    Chari, A.
    Gupta, I
    Paul, S.
    Opalinska, J.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [24] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Degli Esposti, Simona
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
  • [25] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
    Cohen, Adam D.
    Trudel, Suzanne
    Lonial, Sagar
    Libby, Edward N.
    Lee, Hans Chulhee
    Besemer, Britta
    Facon, Thierry
    Nooka, Ajay K.
    Callander, Natalie Scott
    Chari, Ajai
    Gupta, Ira
    Paul, Sofia
    Opalinska, Joanna
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)
    Kortuem, M.
    Terpos, E.
    Badros, A.
    Popat, R.
    Rodriguez-Otero, P.
    Farooq, A.
    Jeng, B.
    Esposti, Degli S.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    Palumbo, A.
    Trudel, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 204
  • [27] Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
    Suvannasankha, A.
    Prawitz, T.
    Kapetanakis, V.
    Sarri, G.
    Hughes, R.
    Wang, F.
    Hogea, C.
    Ferrante, S. Allen
    Gutierrez, B.
    Gorsh, B.
    Willson, J.
    Popat, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S654 - S654
  • [28] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
  • [29] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [30] Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.
    Hultcrantz, Malin
    Kleinman, David
    Ghataorhe, Pavandeep
    McKeown, Astrid
    He, Wei
    Ling, Thomas
    Jewell, Roxanne C.
    Byrne, Julie
    Eliason, Laurie
    Scott, Emma Catherine
    Opalinska, Joanna
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345